Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Dec;38(12):2902–2904. doi: 10.1128/aac.38.12.2902

In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.

S K Spangler 1, M R Jacobs 1, P C Appelbaum 1
PMCID: PMC188304  PMID: 7695280

Abstract

In vitro susceptibility of 185 penicillin-susceptible and -resistant pneumococci to WY-49605, a new oral penem, was compared with susceptibility to penicillin G, amoxicillin with and without clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. WY-49605 yielded MICs for 50 and 90% of the strains tested (MIC50 and MIC90, respectively) of 0.03 and 0.06, 0.125 and 0.5, and 0.5 and 1.0 micrograms/ml, respectively, against penicillin-susceptible, intermediately resistant, and fully resistant strains, respectively. The MIC50 and MIC90 for both amoxicillin and amoxicillin-clavulanate were identical and approximately 1 doubling dilution higher than those for WY-49605 and were < or = 0.06 and 0.125, 0.25 and 1.0, and 1.0 and 1.0 micrograms/ml, respectively. Cephalosporin MIC90s were all significantly higher than those of the latter three compounds for intermediately resistant and fully resistant strains.

Full text

PDF
2902

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Bergan T., da Fonseca J. Comparative antibacterial activity of the penem ALP 201. Chemotherapy. 1991;37(6):413–419. doi: 10.1159/000238888. [DOI] [PubMed] [Google Scholar]
  3. Jacobs M. R. Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1992 Jul;15(1):119–127. doi: 10.1093/clinids/15.1.119. [DOI] [PubMed] [Google Scholar]
  4. Liñares J., Alonso T., Pérez J. L., Ayats J., Domínguez M. A., Pallarés R., Martín R. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother. 1992 Sep;30(3):279–288. doi: 10.1093/jac/30.3.279. [DOI] [PubMed] [Google Scholar]
  5. Liñares J., Pallares R., Alonso T., Perez J. L., Ayats J., Gudiol F., Viladrich P. F., Martin R. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 1992 Jul;15(1):99–105. doi: 10.1093/clinids/15.1.99. [DOI] [PubMed] [Google Scholar]
  6. Nishino T., Maeda Y., Ohtsu E., Koizuka S., Nishihara T., Adachi H., Okamoto K., Ishiguro M. Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem. J Antibiot (Tokyo) 1989 Jun;42(6):977–988. doi: 10.7164/antibiotics.42.977. [DOI] [PubMed] [Google Scholar]
  7. Nord C. E., Lindmark A., Persson I. Susceptibility of anaerobic bacteria to ALP 201. Antimicrob Agents Chemother. 1989 Dec;33(12):2137–2139. doi: 10.1128/aac.33.12.2137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rylander M., Nord C. E., Norrby S. R. Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1989 Oct;8(10):919–924. doi: 10.1007/BF01963784. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES